West Branch Capital’s Corcept Therapeutics CORT Stock Holding History

West Branch Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-142	Closed	-$4.94K	–	388
2025 Q4	$4.94K	Buy	+142	New	+$11.2K	﹤0.01%	312

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

West Branch Capital's CORT Position: Q1 2026 in Review

West Branch Capital sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 142 shares — an estimated $4.94K sold.

West Branch Capital first reported a position in CORT in Q4 2025 and held it in 1 quarter. The position peaked at $4.94K in Q4 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

West Branch Capital reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
West Branch Capital sold 142 Corcept Therapeutics shares in Q1 2026, an estimated $4.94K.
West Branch Capital first reported a position in Corcept Therapeutics in Q4 2025 and held it in 1 quarter.
West Branch Capital's Corcept Therapeutics position peaked at $4.94K in Q4 2025.
352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on West Branch Capital's 13F filing for Q1 2026, filed 14 Apr 2026.